Antitrust enforcers roll out draft guidelines amid crackdown on pharmaceutical mergers
The Federal Trade Commission and Department of Justice unveiled new draft merger guidelines on Wednesday that provide a regulatory framework for the agency’s tougher stance on mergers, including in the pharmaceutical sector.
Antitrust enforcers, which once focused on direct competition, have taken a wider approach to examine how pharmaceuticals leverage their negotiating power. The shift was signaled in a workshop last year, but the agency has sought to strengthen its legal position by formally releasing updated guidelines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.